Harvard doctors backed by HK tycoon Li Ka Shing develop treatment-matching platform for cancer care

Mr Li Ka Shing's investment arm Horizon Ventures said it had invested in Driver because of the rising need for a new platform to connect patients with novel therapies as cancer cases surge globally.
Mr Li Ka Shing's investment arm Horizon Ventures said it had invested in Driver because of the rising need for a new platform to connect patients with novel therapies as cancer cases surge globally.PHOTO: AFP

SHANGHAI (BLOOMBERG) - A pair of Harvard-trained American oncologists, backed by Hong Kong billionaire Li Ka Shing, are attempting to harness technology to revamp cancer care. They're taking some of their earliest steps in China - cancer's ground zero.

China has the world's largest number of cancer patients, yet specialised treatment is in such short supply that patients must often travel long distances to top hospitals, living in dilapidated housing for months for short oncologist visits.

That problem has begun drawing the attention of big name investors, and Mr Li, one of Asia's richest men, in 2015 became the first funder for the physicians' start-up, called Driver.

Other investors joined, and now backed with US$100 million (S$137 million), the firm is developing technology to give cancer patients more control over their care.

It begins formally signing up patients in China and the United States this week, after a 17-month trial run with several hundred people.

The hope is to use technology to address a perennial problem at the heart of global oncology.

The range of cancer drugs and experimental treatments has exploded, and US$133 billion worldwide is spent on these medicines each year, according to researcher Iqvia Institute.

Yet, patients often can't find all the available options, except filtered through an overworked oncologist. Researchers, meanwhile, can't always stay abreast of other studies - sometimes even inside their own vast medical institutions.

Driver's solution? To analyse patient tumours, DNA and other medical records in the start-up's labs in San Francisco and southern China, and create an app to show patients the best treatments and clinical trials globally that match their specific tumours.

Driver works in both countries. Yet, the information shortfalls it is focused on are particularly visible in China: There are just 18 oncologists per one million people in China, compared with 161 for the same number in the US, according to a paper in the Journal of Global Oncology.

"There is an air gap between knowledge and patients that has existed in cancer care since the 1850s," said Driver co-founder Will Polkinghorn. "We want to close that space."


Driver's first major partnership has also appeared in China: The Beijing-based National Cancer Centre, the central agency for cancer research though which 840,000 patients pass through annually.

Next week, the NCC plans to officially announce its use of Driver's platform to manage the more than 200 clinical trials it has running at any one time.

"Prior to Driver, we were managing this manually," said the NCC's clinical trial office director Li Ning. "It's provided a systematic ability for researchers and doctors to recruit patients and keep track of trials going on within the institution."

But for its biggest ambitions to be realised, Driver will needs large swathes of patients to sign up. The full service, including tumour and records processing, followed by treatment matching and curation, will have a US$3,000 price tag, limiting access to affluent patients.

Dr Polkinghorn was a radiation oncologist at Memorial Sloan-Kettering, one of the biggest cancer treatments centres in the US, and his co-founder, Dr Petros Giannikopoulos, was a pathologist at Harvard Medical School when they came up with the idea.

Both were graduates from Harvard Medical School, but funding in Silicon Valley proved elusive. They found luck in Hong Kong, where they landed money from Horizons Ventures, a fund run by Mr Li Ka Shing's companion Solina Chau, and the primary channel of investment for his wealth.

Their board members now include gene-editing pioneer Jennifer Doudna and fashion designer and cancer advocate Tory Burch. They didn't specify how much of the total US$100 million came from Mr Li Ka Shing or who the other investors are.

Horizons Ventures said in a statement that it had invested in Driver because of the rising need for a new platform to connect patients with novel therapies as cancer cases surge globally.


In the US, the government's primary agency for cancer research, the National Cancer Institute, has signed up to be Driver's partner, making information on its clinical trials available on the start-up's platform. It has also validated Driver's treatment matching system.

Mr Matthew Brown, China director of NCI in Beijing, said the access to Chinese patients could facilitate cancer research. For example, he said, if Chinese users agreed to have their scans uploaded anonymously to a global imaging database, that would greatly expand scientists' understanding of how certain cancers develop.

The vast patient body of China's National Cancer Centre could help draw users. Mr Li Ning said that since its doctors were using Driver as an internal management tool, it was "possible" that they would recommend patients sign up for the app, although they aren't obliged to do so. Driver is not charging the NCC for the use of its platform.


Not all patients - especially in China - may feel up to taking a more active role in treatment decisions.

"In Asia, decision-making can also be a lot more paternalistic, as patients have the tendency to defer to and rely on the doctor," said Mr Joseph Kim, senior adviser in Clinical Development Innovation at Eli Lilly & Co.

In Miami, Mr Jesus Loreto used Driver earlier this year to find options for prostate cancer that didn't involve hormone treatments, which he worried might have side effects. Driver curated a list of around nine trials that matched his requirements.

"My oncologist is good, but he would only recommend me trials at his institution, and he didn't recommend new possibilities for me, like doing a liquid biopsy," said the 66-year-old former pharmaceutical executive.

Mr Loreto said he didn't end up enrolling in any trials, as his condition remained stable. Still, "having access to Driver helped me fill the gaps in the information I wanted", he said.